# Thermo Fisher (TMO) — News

TMO · NYSE · Stock

Canonical page: https://www.lighthorse.io/tickers/tmo/news

## Recent headlines

- [Thermo Fisher Scientific Inc: TD Cowen raises target price to $760 from $675](https://www.ainvest.com/news/thermo-fisher-scientific-td-cowen-raises-target-price-760-675-2610) — AInvest Wire, Oct 13, 2026
  TD Cowen has revised its price target for Thermo Fisher Scientific Inc (TMO), raising it to $760 from a previous estimate of $675. The adjustment reflects the firm’s updated assessment of the company’s financial outlook and market positioning. While no specific earnings or operational data from…
- [Verici DX PLC - Wrap retail offer for up to GBP 250,000](https://www.ainvest.com/news/verici-dx-plc-wrap-retail-offer-gbp-250-000-2610) — AInvest Wire, Oct 9, 2026
  Verici Dx plc (AIM: VRCI) has announced a retail offer to raise up to GBP 250,000 through a wrap offer of new ordinary shares. The offer is part of a broader fundraising initiative aimed at accelerating commercial growth and supporting the expansion of revenues from its flagship product, Tutivia™,…
- [Quantum Biopharma - Thermo Fisher to support phase 2 Lucid-MS clinical trial implementation](https://www.ainvest.com/news/quantum-biopharma-thermo-fisher-support-phase-2-lucid-ms-clinical-trial-implementation-2610) — AInvest Wire, Oct 6, 2026
- [Forbion raises $2.68: WSJ](https://www.ainvest.com/news/forbion-raises-2-68-wsj-2610) — AInvest Wire, Oct 6, 2026
  Forbion, a global venture capital firm specializing in life sciences, has raised over €2 billion ($2.2 billion) for its two newest funds, Forbion Growth Opportunities Fund III and Forbion Ventures Fund VII, according to a recent announcement. The funds now bring the firm’s total assets under…
- [Quantum Biopharma signs contract with Thermo Fisher Scientific’s clinical research business to implement phase 2 Lucid-MS trial in multiple sclerosis](https://www.ainvest.com/news/quantum-biopharma-signs-contract-thermo-fisher-scientific-clinical-research-business-implement-phase-2-lucid-ms-trial-multiple-sclerosis-2610) — AInvest Wire, Oct 6, 2026

## Similar Stocks

- [WST](https://www.lighthorse.io/tickers/wst) — West Pharmaceutical Services, Inc. Common Stock
- [MEDP](https://www.lighthorse.io/tickers/medp) — Medpace Holdings, Inc. - Common Stock
- [MCK](https://www.lighthorse.io/tickers/mck) — McKesson Corporation Common Stock
- [AMN](https://www.lighthorse.io/tickers/amn) — AMN Healthcare Services Inc
- [BIO](https://www.lighthorse.io/tickers/bio) — Bio-Rad Laboratories, Inc. Class A Common Stock
- [A](https://www.lighthorse.io/tickers/a) — Agilent Technologies, Inc. Common Stock
- [DHR](https://www.lighthorse.io/tickers/dhr) — Danaher Corporation Common Stock
- [QGEN](https://www.lighthorse.io/tickers/qgen) — Qiagen N.V. Common Shares
- [BIO.B](https://www.lighthorse.io/tickers/bio.b) — Bio-Rad Laboratories, Inc. Class B  Common Stock
- [ILMN](https://www.lighthorse.io/tickers/ilmn) — Illumina, Inc. - Common Stock

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).